Project Details
Projekt Print View

EXC 306:  Inflammation at Interfaces

Subject Area Microbiology, Virology and Immunology
Term from 2007 to 2018
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 49701054
 
Final Report Year 2019

Final Report Abstract

Chronic Inflammatory Barrier Diseases (CIBD) emerged as an increasing challenge due to their systemic biological effects on the organism and the complex interaction between genetic and environmental factors. In the Cluster’s first funding period (FP-1), the hypothetical disease model led the research process in a linear fashion from a few anticipated disease gene identifications to structure, evolutionary and functional annotation and exploration in patients. However, the unprecedented complexity and breadth of etiologic findings prompted a different approach in the second funding period (FP-2), in which our research strategy was developed further with Research Areas (RA) investigating in-depth key genetic, genomic and functional elements of inflammatory diseases while interacting with Cluster Laboratories (CL). The Cluster “Inflammation at Interfaces” combined the expertise and (inter-)national collaborations of a unique multidisciplinary team of >250 scientists from ten disciplines to drive the research of CIBD. A major achievement of the last decade is a profound change in the scientific culture and governance at all participating institutions/faculties, which has contributed to a significant increase in scientific productivity and visibility. Our local development is unique in its combination of disciplines and its strong concentration on clinical translation. This comprises a critical mass in interdisciplinary patient access across the entire field of CIBD, including re-organization of care for inflammation patients from different subspecialties in Comprehensive Centers for Inflammation Medicine (CCIM). This supports large cohort studies and therapeutic trials. The interdisciplinary research culture that resulted from this structural innovation has led to an outstanding series of high-impact findings. For example, Cluster scientists have led or contributed to many published international genetic meta-analyses and GWAS analyses for CIBD entities. Another developmental highlight of this Cluster was the development of an IL-6 trans-signaling inhibitor, which is currently being tested in a phase 2 trial for a CIBD. Our ongoing Cluster “Precision Medicine in Chronic Inflammation” (PMI) is based on the achievements of the previous Cluster and aims to describe an individual molecular efficacy signature for therapies in patients and will prompt individual choices of anti-inflammatory therapies in the future. The setup of a medical systems biology and a massive investment in IT were important pre-requirements and achievements of the FP-2. The ultimate goal of the new Cluster PMI is to define inflammatory barrier disease at early, not yet clinical, stages once it has reached a point-of-no-return and to develop rational interventions which intercept the further course.

Link to the final report

https://dx.doi.org/10.2314/KXP:1697278027

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung